Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Adcendo secures $75m in Series C funding for ADC development

 April 15, 2026

Pharmaceutical Technology

Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.

M&A / DealsOncologyRead full story

Post navigation

Adcendo secures $75m in Series C funding for ADC development →
← Lilly to acquire CrossBridge Bio for up to $300m

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com